Search results
Results from the WOW.Com Content Network
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZUG, Switzerland and BOSTON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today presented data from the Company’s ongoing Phase 1/2 dose escalation clinical trial evaluating the safety and efficacy of CTX112™, a ...
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.75% and 139.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for ...
CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. But don't expect CRISPR to try to offload ...
CRISPR Therapeutics AG (CRSP) closed at $67.66 in the latest trading session, marking a +0.71% move from the prior day.
CRISPR Therapeutics AG (CRSP) closed at $54.33 in the latest trading session, marking a -0.93% move from the prior day. CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should ...
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland.It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases.